Product Code: A03484
The global ENT disorder treatment market was valued at $2,370.59 million in 2021, and is projected to reach $4,496.58 million by 2031, registering a CAGR of 6.5% from 2022 to 2031.
Ear, nose and throat are vital parts of the body. Ear is the sensory organ which is responsible to hear sounds, and to maintain the overall balance of the body. Nose is another type of sensory organ which helps to recognize smell; it also works as a defense mechanism restricting the entry of foreign particles, whereas, the throat provides the passage for air, water, and food.
Malfunction in any of these organs due to various diseases can directly affect the quality of life. Some of the common types of ENT disorders are ear-infection, sinus infection, tonsilitis, acoustic neuroma, Meniere's disorder and others. The ENT disorder treatment consists of wide range of drugs such as nasal decongestion sprays, oral and topical anti-histamines, nasal steroids and nasal saline washes. Moreover, to treat ear infection a wide range of antibiotics are available; furthermore, a number of medical devices are also available to cure the presbycusis.
The key factors that drive the growth of market are rapid changes in environmental conditions and the increase in the level of air and noise pollution and rise in geriatric population. As geriatric population is more susceptible to get infected easily due to poor immune system which further propels the growth of the market. For instance, according to the report published by the technical group on population projections for India, about138 million were aged above 60 in India in 2021 and this is further expected to increase in 2031. Thus, increase in the geriatric population surged the demand for ear drops, and antibiotics to treat nasal, ear & throat infection, which drives the growth of the market.
Moreover, rise in the prevalence of sinusitis and chronic rhinitis across the world further drives the growth of market. In addition, rise in healthcare expenditure and increase in government initiatives in developing countries are the key factors that further boost the market growth
However, the high cost of medical devices and for the surgeries for sinusitis and tonsillitis hampers the market growth. Conversely, emerging healthcare market in developing countries is expected to provide the lucrative opportunity for the growth of market during the forecast period.
The ENT disorder treatment market is segmented on the basis of drug type, organ, end user and region. By drug type it is segmented into antibiotics, anti-inflammatory and others. By organ, it is segmented into ear, nose and throat. By end user the market is segmented into hospitals and clinics, homecare settings and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
North America accounted for a majority of the ENT disorder treatment market share in 2021 and is anticipated to remain dominant during the forecast period owing to the increase in the healthcare expenditure of this region and presence of major players in the country and the strategies they adopt for their product development.
Asia-Pacific was the second largest contributor to the market in 2021, and is expected to register the fastest CAGR during the forecast period, owing to increase in the environmental pollution, rise in geriatric population and rise in prevalence of nasal infection, infectious and allergic conditions.
The key players that operate in the ENT disorder treatment market are Sanofi, Novartis, GSK, Pfizer, Vitaris, Sun Pharma, AstraZeneca, Cipla, AurbindoPharma, Teva Pharmaceuticals, Bayer AG, Amneal Pharmaceuticals Ltd, M.M Pharma, Lyra Therapeutics, Lannet Company Inc.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the ent disorder treatment market analysis from 2021 to 2031 to identify the prevailing ent disorder treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the ent disorder treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global ent disorder treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Type
- Antibiotics Drugs
- Anti Inflammatory Drugs
- Others
By Organ
- Throat
- Disease Type
- Tonsillitis
- Pharyngitis
- Tonsillopharyngitis
- Others
- Ear
- Disease Type
- Otitis Media
- Otitis Externa
- Meniere's Disease
- Otomycosis
- Others
- Nose
- Disease Type
- Sinusitis
- Rhinitis
- Nasal Polyps
- Others
By End User
- Others
- Hospital and clinics
- Homecare Settings
By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest Of Asia- Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Pfizer Inc
- Teva Pharmaceuticals
- Novartis
- Glaxosmithkline plc
- Bayer Ag
- Sanofi
- Amneal Pharmceuticals Ltd
- Astrazenca Plc
- Mylan N.V.
- Akira Healthcare
- Aurbindo pharma
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter's five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: ENT DISORDER TREATMENT MARKET, BY DRUG TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Antibiotics Drugs
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Anti Inflammatory Drugs
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Others
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
CHAPTER 5: ENT DISORDER TREATMENT MARKET, BY ORGAN
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Throat
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.2.4 Throat ENT Disorder Treatment Market by Disease Type
- 5.2.4.1 Tonsillitis Market size and forecast, by region
- 5.2.4.2 Pharyngitis Market size and forecast, by region
- 5.2.4.3 Tonsillopharyngitis Market size and forecast, by region
- 5.2.4.4 Others Market size and forecast, by region
- 5.3 Ear
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.3.4 Ear ENT Disorder Treatment Market by Disease Type
- 5.3.4.1 Otitis Media Market size and forecast, by region
- 5.3.4.2 Otitis Externa Market size and forecast, by region
- 5.3.4.3 Meniere's Disease Market size and forecast, by region
- 5.3.4.4 Otomycosis Market size and forecast, by region
- 5.3.4.5 Others Market size and forecast, by region
- 5.4 Nose
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- 5.4.4 Nose ENT Disorder Treatment Market by Disease Type
- 5.4.4.1 Sinusitis Market size and forecast, by region
- 5.4.4.2 Rhinitis Market size and forecast, by region
- 5.4.4.3 Nasal Polyps Market size and forecast, by region
- 5.4.4.4 Others Market size and forecast, by region
CHAPTER 6: ENT DISORDER TREATMENT MARKET, BY END USER
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Hospital and clinics
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Homecare Settings
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Others
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
CHAPTER 7: ENT DISORDER TREATMENT MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Drug Type
- 7.2.3 North America Market size and forecast, by Organ
- 7.2.3.1 North America Throat ENT Disorder Treatment Market by Disease Type
- 7.2.3.2 North America Ear ENT Disorder Treatment Market by Disease Type
- 7.2.3.3 North America Nose ENT Disorder Treatment Market by Disease Type
- 7.2.4 North America Market size and forecast, by End User
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Drug Type
- 7.2.5.1.2 Market size and forecast, by Organ
- 7.2.5.1.3 Market size and forecast, by End User
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Drug Type
- 7.2.5.2.2 Market size and forecast, by Organ
- 7.2.5.2.3 Market size and forecast, by End User
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Drug Type
- 7.2.5.3.2 Market size and forecast, by Organ
- 7.2.5.3.3 Market size and forecast, by End User
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Drug Type
- 7.3.3 Europe Market size and forecast, by Organ
- 7.3.3.1 Europe Throat ENT Disorder Treatment Market by Disease Type
- 7.3.3.2 Europe Ear ENT Disorder Treatment Market by Disease Type
- 7.3.3.3 Europe Nose ENT Disorder Treatment Market by Disease Type
- 7.3.4 Europe Market size and forecast, by End User
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Drug Type
- 7.3.5.1.2 Market size and forecast, by Organ
- 7.3.5.1.3 Market size and forecast, by End User
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Drug Type
- 7.3.5.2.2 Market size and forecast, by Organ
- 7.3.5.2.3 Market size and forecast, by End User
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Drug Type
- 7.3.5.3.2 Market size and forecast, by Organ
- 7.3.5.3.3 Market size and forecast, by End User
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Drug Type
- 7.3.5.4.2 Market size and forecast, by Organ
- 7.3.5.4.3 Market size and forecast, by End User
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Drug Type
- 7.3.5.5.2 Market size and forecast, by Organ
- 7.3.5.5.3 Market size and forecast, by End User
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Drug Type
- 7.3.5.6.2 Market size and forecast, by Organ
- 7.3.5.6.3 Market size and forecast, by End User
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Drug Type
- 7.4.3 Asia-Pacific Market size and forecast, by Organ
- 7.4.3.1 Asia-Pacific Throat ENT Disorder Treatment Market by Disease Type
- 7.4.3.2 Asia-Pacific Ear ENT Disorder Treatment Market by Disease Type
- 7.4.3.3 Asia-Pacific Nose ENT Disorder Treatment Market by Disease Type
- 7.4.4 Asia-Pacific Market size and forecast, by End User
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Drug Type
- 7.4.5.1.2 Market size and forecast, by Organ
- 7.4.5.1.3 Market size and forecast, by End User
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Drug Type
- 7.4.5.2.2 Market size and forecast, by Organ
- 7.4.5.2.3 Market size and forecast, by End User
- 7.4.5.3 Australia
- 7.4.5.3.1 Market size and forecast, by Drug Type
- 7.4.5.3.2 Market size and forecast, by Organ
- 7.4.5.3.3 Market size and forecast, by End User
- 7.4.5.4 India
- 7.4.5.4.1 Market size and forecast, by Drug Type
- 7.4.5.4.2 Market size and forecast, by Organ
- 7.4.5.4.3 Market size and forecast, by End User
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Drug Type
- 7.4.5.5.2 Market size and forecast, by Organ
- 7.4.5.5.3 Market size and forecast, by End User
- 7.4.5.6 Rest Of Asia- Pacific
- 7.4.5.6.1 Market size and forecast, by Drug Type
- 7.4.5.6.2 Market size and forecast, by Organ
- 7.4.5.6.3 Market size and forecast, by End User
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Drug Type
- 7.5.3 LAMEA Market size and forecast, by Organ
- 7.5.3.1 LAMEA Throat ENT Disorder Treatment Market by Disease Type
- 7.5.3.2 LAMEA Ear ENT Disorder Treatment Market by Disease Type
- 7.5.3.3 LAMEA Nose ENT Disorder Treatment Market by Disease Type
- 7.5.4 LAMEA Market size and forecast, by End User
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Drug Type
- 7.5.5.1.2 Market size and forecast, by Organ
- 7.5.5.1.3 Market size and forecast, by End User
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Drug Type
- 7.5.5.2.2 Market size and forecast, by Organ
- 7.5.5.2.3 Market size and forecast, by End User
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Drug Type
- 7.5.5.3.2 Market size and forecast, by Organ
- 7.5.5.3.3 Market size and forecast, by End User
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Drug Type
- 7.5.5.4.2 Market size and forecast, by Organ
- 7.5.5.4.3 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
CHAPTER 9: COMPANY PROFILES
- 9.1 Pfizer Inc
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Teva Pharmaceuticals
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Novartis
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Glaxosmithkline plc
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Bayer Ag
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Sanofi
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Amneal Pharmceuticals Ltd
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Astrazenca Plc
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Mylan N.V.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Akira Healthcare
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- 9.11 Aurbindo pharma
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments